Interleukin-20 receptor alpha (IL20RA) is a transmembrane protein that forms part of the heterodimeric receptor complex for IL-19. IL-20. and IL-24. cytokines belonging to the IL-10 family. It pairs with IL20RB or IL22RA1 to mediate downstream signaling, primarily activating the JAK-STAT pathway. IL20RA is expressed in epithelial tissues, immune cells, and endothelial cells, playing roles in skin homeostasis, inflammatory responses, and tissue repair. Dysregulation of IL20RA signaling is linked to chronic inflammatory diseases, such as psoriasis, rheumatoid arthritis, and atherosclerosis, making it a potential therapeutic target.
IL20RA antibodies are tools used to study receptor localization, expression levels, and signaling mechanisms in disease models. Neutralizing antibodies targeting IL20RA have been explored in preclinical studies to block pro-inflammatory cytokine activity, showing promise in reducing pathological inflammation and tissue damage. Additionally, diagnostic applications include detecting IL20RA overexpression in diseased tissues. Commercial IL20RA antibodies are typically validated for techniques like Western blot, immunohistochemistry, and flow cytometry. Research continues to clarify its interactions with ligands and coreceptors, as well as its tissue-specific functions, aiding drug development for immune-mediated disorders.